GSK at a glance

Male scientist and female dressed smartly smiling in a studio

Download

GSK at a glance (PDF, 1.0MB)

A focused biopharma company

People worldwide
70k
Countries we operate in
>75
Manufacturing sites
37

Innovation

R&D investment in 2023 (£)
6.2bn
Global R&D centres in US, UK, Belgium and Italy
4
Major business development deals in 2023
6

Performance

Packs of medicines and doses of vaccines delivered
2.3bn
Vaccine and medicine sales in 2023 (£)
30.3bn
Sales growth in 2023
14%
Sales of products launched in the last five years including lifecycle innovation (£)
10bn

Trust

In the Access to Medicine Index
1st
In our industry for the S&P Global Corporate Sustainability Assessment
1st
Reduction in Operational Carbon emissions
10%
Global Health pipeline assets progressed to address priority WHO Diseases
12

Products and pipeline

Assets in the pipeline
71
Number of phase I programmes started in 2023
8
Number of assets in phase III/registration in 2023
18
Major new vaccines and medicines approved in 2023
4

Vaccine preventable diseases identified by WHO
23/32
Vaccine doses delivered each day
1.5m
Children receiving a GSK vaccine each year
4 in 10
Candidate vaccines in our pipeline
19

To pioneer HIV treatments in 1980 and leaders in HIV innovation
1st
To produce a new medicine for Lupus in 50+ years
1st
Investigational medicines in our oncology pipeline
11

Patients reached with our general medicines over the next ten years
700m
Medicines in our portfolio
150+
Helping millions of people with respiratory conditions to breathe more easily
50 years
In 2023 sales grew to (£)
10.2bn

Key achievements

Malaria vaccine

Our ground-breaking malaria vaccine is the first and only vaccine shown in long-term clinical trials to reduce malaria in children.

Infectious diseases

Major approvals

We delivered four major product approvals in 2023 for infectious diseases, HIV and oncology.

HIV

Monoclonal antibodies

We have developed monoclonal antibodies to help treat different diseases. Monoclonal antibodies are laboratory-made proteins that work in a similar way to antibodies in the human immune system.

Respiratory/immunology

Cancer medicines

We have 11 investigational medicines in our oncology pipeline that have the potential to make a meaningful difference for patients with cancer, and we’re growing our pipeline through targeted business development.

Oncology